Essentials• Bleeding is a common cause of hospital admission and readmission in oral
anticoagulant users.• Patients with dabigatran and warfarin were included to assess hospital …

Objective: To determine the incidence and severity of bleeding events requiring
hospitalization among patients with atrial fibrillation (AF) receiving anticoagulants …

Data comparing the patient characteristics, management and outcomes for dabigatran
versus warfarin major bleeding in the practice setting are limited. We performed a …

BACKGROUND: Oral anticoagulation such as warfarin and dabigatran is indicated for atrial
fibrillation (AF) patients at risk of ischemic stroke. Dabigatran etexilate was developed to …

Dabigatran is approved for stroke risk reduction in patients with nonvalvular atrial fibrillation
(NVAF). Data from diverse clinical practice settings will help establish whether the risk …

Objective: Clinical trials have demonstrated that direct oral anticoagulants (DOACs) are
efficacious in reducing stroke risk among patients with nonvalvular atrial fibrillation (NVAF) …

Background Antithrombotic therapy, including direct oral anticoagulants, is recommended in
patients with non-valvular atrial fibrillation (NVAF) who are at intermediate-to-high risk of …

STUDY OBJECTIVE: Dabigatran is a reversible direct thrombin inhibitor recently approved
for stroke prevention in patients with atrial fibrillation. An increasing number of patients …

Background and Purpose—Little is known about the clinical outcomes associated with
posthemorrhage anticoagulation resumption for atrial fibrillation. This study had 2 objectives …

Study Objectives To identify demographic and clinical risk factors associated with
gastrointestinal (GI) bleeding among a large cohort of patients with atrial fibrillation (AF) who …